X

Trial Profile

A Phase 1b Study of Combined Angiogenesis Inhibition by Administering REGN910 and Aflibercept (Ziv-aflibercept) in Patients With Advanced Solid Malignancies

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 19 Mar 2015

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aflibercept (Primary) ; Nesvacumab (Primary)
Indications Ovarian cancer; Solid tumours
Focus Adverse reactions
Sponsors Regeneron Pharmaceuticals

Most Recent Events

16 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
08 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
23 Nov 2013 New source identified and integrated (Memorial Sloan-Kettering Cancer Center: 13-156).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com